Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer

Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer ( Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy )

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer

Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer ( Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan )

Choosing cancer medicines wisely in Africa

Dr Harrison Chuwa - Aga Khan Hospital, Dar es Salaam, Tanzania

Choosing cancer medicines wisely in Africa ( Dr Harrison Chuwa - Aga Khan Hospital, Dar es Salaam, Tanzania )

Test identifies tumour-infiltrating cell densities as prognostic biomarkers across a pan-cancer cohort

Dr James Lindsay - Dana Farber Cancer Institute, Boston, USA

Test identifies tumour-infiltrating cell densities as prognostic biomarkers across a pan-cancer cohort ( Dr James Lindsay - Dana Farber Cancer Institute, Boston, USA )

A multidisciplinary team approach to cancer care in the Philippines

Dr Arnold John Uson - Perpetual Succour Hospital of Cebu, Cebu, Philippines

A multidisciplinary team approach to cancer care in the Philippines ( Dr Arnold John Uson - Perpetual Succour Hospital of Cebu, Cebu, Philippines )

The 2022 OncoAlert Colloquium Day 6: EONS Sessions

Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden

The 2022 OncoAlert Colloquium Day 6: EONS Sessions ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )

The 2022 OncoAlert Colloquium Day 5: GI Oncology

Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden

The 2022 OncoAlert Colloquium Day 5: GI Oncology ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )

The 2022 OncoAlert Colloquium Day 4: ESGO Sessions and Gynaecological Oncology

Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden

The 2022 OncoAlert Colloquium Day 4: ESGO Sessions and Gynaecological Oncology ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )

The 2022 OncoAlert Colloquium Day 3: Lung Cancer

Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden

The 2022 OncoAlert Colloquium Day 3: Lung Cancer ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )

The 2022 OncoAlert Colloquium Day 2: GU Oncology

Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden

The 2022 OncoAlert Colloquium Day 2: GU Oncology ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )

The 2022 OncoAlert Colloquium Day 1: Breast Cancer

Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden

The 2022 OncoAlert Colloquium Day 1: Breast Cancer ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer

Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer ( Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA )

More from ecancer